Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atmos Energy

Clorox

Federal Realty Investment Trust

PepsiCo

While the market rebounded smartly from the late September selling spree, where we finally reached a 5% decline after nearly a year without one, storm clouds are on the horizon once again.

5 Safe and Dependable Dividend Aristocrat Stocks are Perfect Q4 Buys Now

Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

With 9,000 stores in the US, Walgreens is able to reach 80% of U.S. consumers.

Walgreens: Good Bye Vs. Good Buy

Bristol-Myers

Buying above-average companies at below-average prices is generally a winning strategy. I highlight 2 such blue-chip companies whose stocks have been beaten down by the market.

Not 1, But 2 Dividend Gifts From The Market

Amgen

Boeing

Caterpillar

Cisco Systems

Chevron

Disney

Dow Inc

Intel

Coca-Cola

Merck

NIKE

Visa

Verizon

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."

A 6% October Pullback Can Spring 3 Dogs Of The Dow For Dividend Income

NEW YORK--(BUSINESS WIRE)--No7 Beauty Company expands its cult favorite Advanced Retinol 1.5% Complex Night Concentrate with the expansion of the new Pure Retinol Collection.

No7 Beauty Company Launches Pure Retinol Collection – Effective Skincare Formulated to Be Gentler for Everyday Use

AGNC Investment

Big-time bargains are available for opportunistic long-term investors.

3 Value Stocks That'll Make You Richer in the Fourth Quarter (and Beyond)

Despite big gains year to date, Walgreens Boots Alliance still looks undervalued at current levels, with potential annual gains of 7% to 15%. The post Best Stocks for 2021: Walgreens Boots Alliance Still A Cheap Stock to Buy appeared first on InvestorPlace.

Best Stocks for 2021: Walgreens Boots Alliance Still A Cheap Stock to Buy

CVS Health

Four large pharmacy chains, including Walgreens Boots Alliance Inc (NYSE: WBA), CVS Health Corp (NYSE: CVS), Walmart Inc (NYSE: WMT), and Giant Eagle Inc, will face their first trial over the U.S. opioid epidemic, Reuters reported. The Ohio counties of Lake and Trumbull allege that oversight failures led to excessive amounts of opioid pills in their communities.

After Drug Distributors, Now Pharmacy Chains Face Trial In US Opioid Litigation: Reuters

CINCINNATI--(BUSINESS WIRE)--Today, Walgreens and Safeguard announced an exciting new collaboration with Americares to launch the Hope is in Your Hands program, which will provide 10 million handwashes to communities and families in need. Americares, a health-focused relief and development organization, helps communities prepare for, respond to and recover from disasters; increase access to medicine and medical supplies; improve and expand clinical services; and prevent disease and promote good

Safeguard Hand Soap and Walgreens Collaborate With Americares to Bring 10 Million Handwashes to Communities in Need

Evolent Health

Walgreens Boots Alliance Inc (NASDAQ: WBA) is reportedly mulling an acquisition of Evolent Health Inc (NYSE: EVH). Citing people familiar with the matter, Bloomberg reported that the talks are ongoing, and there is no certainty Walgreens will move forward with an offer to buy the company.

Walgreens In Talks To Buy Evolent Health: Bloomberg

In the latest trading session, Walgreens Boots Alliance (WBA) closed at $48.71, marking a +1.29% move from the previous day.

Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know

Pharmacy chain Walgreens Boots Alliance is considering an acquisition of healthcare IT firm Evolent Health Inc, Bloomberg reported on Wednesday, citing people familiar with the matter.

Walgreens weighing deal to buy Evolent Health - Bloomberg

Evolent Health's stock jumped as much as 18% in afternoon trading Wednesday after Bloomberg reported that Walgreens was considering buying the company.

Evolent Health stock jumps after report of possible Walgreens takeover

Quest Diagnostics

Maravai LifeSciences Holdings

Option Care Health

West Pharmaceutical Services

Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.

3 High-Potential MedTech Stocks With More Than 50% Growth YTD

DEERFIELD, Ill.--(BUSINESS WIRE)-- #WeAreWBA--Walgreens Boots Alliance released its Diversity, Equity and Inclusion Report, which provides updates on the company's leadership diversity progress.

Walgreens Boots Alliance Releases Second Diversity, Equity and Inclusion Report

AbbVie

A. O. Smith

Air Products and Chemicals

Becton, Dickinson and Co.

Chubb

Con Ed

General Dynamics

Hormel Foods

Illinois Tool Works

Lowe's

McDonald's

Nucor

Stanley Black & Decker

Sysco

AT&T

V.F.

NOBL's momentum fades in September hindering its chances of having a record-breaking return this year. I present 3 strategies that theoretically can beat the dividend aristocrat index in the long term.

Best Dividend Aristocrats For October 2021

Apple

Abbott Labs

Amplify Lithium & Battery Technology ETF

Blackrock Inc

Carrier Global

Colgate-Palmolive

Invesco DB Commodity Index Tracking Fund

General Electric

iShares Core S&P 500 ETF

Johnson & Johnson

Medtronic

Microsoft

ProShares S&P 500 Dividend Aristocrats ETF

Otis Worldwide

Procter & Gamble

QUALCOMM

Raytheon Technologies

Texas Instruments

Vanguard Dividend Appreciation ETF

Exxon Mobil

The Dividend Aristocrats have historically beat the market with less volatility. Can you improve your odds by paying attention to certain metrics such as quality or safety?

Going One Better Than The Dividend Aristocrats

News for Walgreens Stock (WBA)